#USA #Franklin Lakes #Becton Dickinson #Revello Stent #Iliac Arteries

BD's Innovative Revello Stent: A New Era for Iliac Artery Treatment in Europe

Introduction

In an essential development for medical technology, BD (Becton, Dickinson and Company) has recently received the CE marking for its Revello™ Vascular Covered Stent. This groundbreaking device is set to revolutionize the treatment of atherosclerotic lesions specifically in the common and external iliac arteries. The approval comes at a vital time as peripheral artery disease (PAD) among the aging population in the European Union poses significant healthcare challenges.

Understanding Peripheral Artery Disease (PAD)

Peripheral artery disease is characterized by reduced blood flow to the limbs due to the accumulation of fatty deposits in the arteries. Particularly prevalent in older adults, PAD can lead to serious complications, including limb ischemia. As Europe’s demographic shifts towards an older population, the demand for effective treatments becomes increasingly critical. According to healthcare experts, conditions affecting the iliac arteries contribute to significant disability among the elderly.

The Revello™ Vascular Covered Stent: Key Features

Technical Innovations

The Revello™ Stent combines the flexibility of a self-expanding Nitinol stent with the radial strength necessary to cater specifically to iliac arteries. This dual functionality is intended to optimize outcomes by maintaining artery patency while adapting to individual vascular anatomies. The stent features:

• - Ultra-thin ePTFE Coating: To ensure the arteries remain unclogged, promoting long-term efficacy.
• - Radiopaque Tantalum Markers: For clear visualization during fluoroscopy, which allows for better positioning even in complex anatomical scenarios.
• - Triaxial Delivery System: Designed for controlled deployment and precise placement, this system includes an atraumatic tip that eases insertion and a stability sheath that aids in accurate implantation.

Comparative Advantages

In comparison to existing iliac artery stents, the Revello™ Stent boasts a more significant diameter range on a lower profile platform, which can potentially mitigate risks associated with access site complications, a common issue in these procedures. Furthermore, multiple catheter lengths enhance procedure versatility, allowing for tailored applications to meet diverse patient needs.

Clinical Implications and Future Directions

During its unveiling at the 2026 LINC Congress in Germany, discussions highlighted the Revello Stent's capabilities and its potential implications for iliac artery interventions. Dr. Michael Lichtenberg, an angiologist involved in ongoing clinical studies, emphasized the stent's high radial force and low-profile design, marking it as a promising new option for treating iliac arterial conditions.

The AGILITY Clinical Study

Currently, the Revello™ Stent is under evaluation in a prospective, multicenter clinical study called AGILITY. This research, led by Dr. Sean Lyden from the Cleveland Clinic, aims to investigate the device's performance in PAD patients. With such clinical support, BD reinforces its commitment to enhancing vascular treatments across Europe.

Conclusion

The introduction of the Revello™ Vascular Covered Stent signifies a pivotal advancement in non-invasive vascular interventions for iliac arteries. As BD continues to push the boundaries of medical technology, healthcare providers in the EU and EEA countries now have access to a vital tool that could significantly improve outcomes for patients suffering from PAD. BD’s ongoing dedication to innovation paves the path for a future where medical professionals can better address complex vascular conditions, ultimately benefiting the health of many across the region.

For more details about BD and its innovative solutions, please visit their official website or connect with them through various social media platforms.